| Survival: | 11.2 months |
| Toxicity Grade: | 4 |
| Treatments: | Chemotherapy |
| Drugs: | Gemzar Platinol |
| Country: | Australia |
| City/State/Province: | Nedlands, WA |
| Hospital: | Sir Charles Gairdner Hospital |
| Journal: | Link |
| Date: | 8/2002 |
| Description: |
| Patients: This Phase II study involved 53 patients with malignant pleural mesothelioma; 45 men and 8 women. The median age was 63 years. Treatment: The treatment consisted of two chemotherapy drugs; cisplatin (platinol) and gemcitabine (gemzar). Toxicity: Grade 3-4 toxicities included hematologic, diarrhea, infection, neurotoxicity, vomiting, and nausea. Results: Median survival was 11.2 months. Support: The study was supported in part by Eli Lilly. This company markets gemzar. Correspondence: M.J. Byrne, MD |